Last reviewed · How we verify
Probiotics Lactobacillus Rhamnosus
Probiotics Lactobacillus Rhamnosus modulates the gut microbiome to improve immune function and overall health.
Probiotics Lactobacillus Rhamnosus modulates the gut microbiome to improve immune function and overall health. Used for Irritable bowel syndrome (IBS), Inflammatory bowel disease (IBD).
At a glance
| Generic name | Probiotics Lactobacillus Rhamnosus |
|---|---|
| Sponsor | Aga Khan University |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
By introducing beneficial bacteria into the gut, Probiotics Lactobacillus Rhamnosus can help restore balance to the microbiome, leading to improved immune system function and overall health. This can have a range of benefits, including reduced inflammation and improved digestion.
Approved indications
- Irritable bowel syndrome (IBS)
- Inflammatory bowel disease (IBD)
Common side effects
- Abdominal pain
- Diarrhea
- Flatulence
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis (PHASE2)
- Probiotic (LGG) for Veterans With PTSD (PHASE2)
- Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer (NA)
- The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee (NA)
- Encapsulated Probiotics & Gut Microbiota (PHASE1)
- Assessment of the Effects of Probiotic Supplementation on Gut Microbiota Composition and Short-chain Fatty Acid Production in Frail Elderly Patients Receiving Home Enteral Nutrition With an Oligomeric Formula. (NA)
- Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotics Lactobacillus Rhamnosus CI brief — competitive landscape report
- Probiotics Lactobacillus Rhamnosus updates RSS · CI watch RSS
- Aga Khan University portfolio CI